Associate Chairman, Dep. of Ped. Oncology, Dana-Farber Cancer Institute: ‘Gene therapy in monogenic diseases, a platform for gene editing in the clinic‘ 11.05.2016 - REBIRTH colloquium ( 5 pm c.t., Lecture [...] p.m.,c.t., lecture hall G) Juan A. Bueren, Ph.D., Head of the Hematopoietic Gene Therapy Division, CIEMAT, Madrid, Spain: Gene Therapy and Cell Reprogramming in Fanconi Anemia 21.06.2010, Special lecture [...] Uhr im Hörsaal Q) ‘The future is here! The next generation of AAV vector as a foundation of cell and gene therapeutics of the future’ Prof. Leszek Lisowski, Translational Vectorology Research Unit, Children’s

Leszek Lisowski „The future is here! The next generation of AAV vector as a foundation of cell and gene therapeutics of the future“ Außerordentlicher Professor Lisowski promovierte an der Weill Cornell

rkrankungen ist. Diese Erkrankungen werden durch monogenetische Mutationen in immunregulierenden Genen verursacht (z.B. CTLA4, LRBA, NFκB1, NFκB2, STAT3, SOCS1, RELA, TNFAIP3, and LAT) und sind typischerweise

Anatomie der Medizinischen Hochschule Hannover (Prof. Dr. R. Pabst) 09/2006 State-approved course „Gene Technology Security“ 04/2008-08/2010 Klinisch-wissenschaftlicher Mitarbeiter in der Klinik für Ps

2003; 13(2): 133-8 Bock O, Serinsöz E, Neusch M, Schlué J, Kreipe H: The Polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate Polycythaemia vera from [...] Marwedel M, Musholt TJ: Frequency of mutations and loss of heterozygosity of the tumor suppressor gene PTEN in sporadic follicular thyroid carcinomas: does PTEN play a role in carcinogenesis? Langenbecks [...] Kreipe HH, Pfeifer GP, Schlegelberger B, Dammann R: Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma. Oncogene 2003; 22(12): 1866-71 Schultheiss D, Badalyan R, Pilatz A, Gabouev

llen Studie zur Rolle der Proteinkinase-C-alpha in der diabetischen Nephropathie in einem murinen Gen-Knock-out-Modell. Seine pädiatrische Ausbildung begann PD Dr. Böhne 2004 im Rahmen des strukturierten

possibility of working in an international environment with interesting projects on the cutting edge of gene therapy, leukemogenesis and vectorology. Please see scientific goals for additional information. For

Down-regulation of the fetal stem cell factor SOX17 by H33342: a mechanism responsible for differential gene expression in breast cancer side population cells. J Biol Chem 2010; 285(9): 6412-8 Claus RA, Bockmeyer [...] rger B, Göhring G: Telomere shortening and chromosomal instability in myelodysplastic syndromes. Genes Chromosomes Cancer 2010; 49(3): 260-9 Lehmann U : [DNA methylation. From basic research to routine [...] Schlegelberger B, Länger F , Kreipe H , Lehmann U : Epigenetic inactivation of tumour suppressor gene KLF11 in myelodysplastic syndromes. Eur J Haematol 2010; 84(4): 298-303 Reich A, Maj J, Schlue J,

Ferreira de Figueiredo (Transfusion Medicine) Project: Correction of monogenetic kidney diseases using a gene therapeutic approach Aavani Biju Sindhu INDIA; Sindhu.Aavani @ mh-hannover.de Supervisor: Prof. Dr [...] Felix @ mh-hannover.de Supervisor: Prof. Dr. Axel Schambach (Experimental Hematology) Project: Novel gene therapy strategies for inherited inner ear defects Lena Willmer GERMANY; lena.willmer @ item.fraunhofer

Robert @ mh-hannover.de Supervisor: Prof. Dr. Axel Schambach (Experimental Hematology) Project: Novel gene and immunotherapeutic approaches for the treatment of cervical cancer Pegah Rahmati IRAN Rahmati.Pegah [...] Pegah @ mh-hannover.de Supervisor: Prof. Dr. Britte Eiz-Vesper (Transfusion Medicine) Project: Gene-regulated EBV-specific T cells for personalized adoptive immunotherapy Final exam November 2024 Sonia